##plugins.themes.bootstrap3.article.main##


Andres Felipe Laserna Estrada

Julián Esteban Barahona Correa

Luz Helena Alba Talero

Resumen

Introducción: la infección por Helicobacter pylori es un problema de salud pública, dada su relación con cáncer gástrico. El incremento de la resistencia bacteriana limita la erradicación efectiva, a pesar del empleo de diferentes esquemas de tratamiento. Métodos: revisión de la literatura en la base de datos Pubmed/Medline entre el 1 de enero de 2015 y el 31 de diciembre de 2016 sobre el manejo del Helicobacter pylori. Resultados: se incluyeron 26 artículos. La terapia secuencial sobresale como opción de tratamiento de primera línea para escenarios como Colombia. La implementación de coadyuvantes puede influir en las tasas de erradicación. Los estudios de epidemiología local y costoefectividad son escasos. Conclusiones: el uso y conocimiento adecuado de los esquemas de manejo puede disminuir los costos para el sistema, la resistencia antimicrobiana y favorecer la erradicación de patógenos. Se requieren estudios para generar recomendaciones locales.

##plugins.themes.bootstrap3.article.details##

Keywords
References
1. Blaser MJ, Atherton JC. Helicobacter pylori persistence: Biology and disease. J Clin Invest. 2004;113(3):321-33.

2. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554-60.

3. Correa P, Piazuelo MB. Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev. 2011;7(1):59-64.

4. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. septiembre de 2015;64(9):1353-67.

5. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302(6788):1302-5.

6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog risks to humans. 1994;61:1-241.

7. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017 Ago;153(2):420-9.

8. Otero WR. Helicobacter pylori en agua potable: ¿Es la ruta de la infección? Acta Med Colomb. 2017;42(2):87-9.

9. Klein PD, Graham DY, Gaillour A, Opekun AR, Smith EO. Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet. 1991 jun 22;337(8756):1503-6.

10. Aziz RK, Khalifa MM, Sharaf RR. Contaminated water as a source of Helicobacter pylori infection: A review. J Adv Res. 2015 jul;6(4):539-47.

11. Bellack NR, Koehoorn MW, MacNab YC, Morshed MG. A conceptual model of water’s role as a reservoir in Helicobacter pylori transmission: A review of the evidence. Epidemiol Infect. 2006 jun;134(3):439-49.

12. Goh K-L, Chan W-K, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011 sep;16 Suppl 1:1-9.

13. Khalifa MM, Sharaf RR, Aziz RK. Helicobacter pylori: A poor man’s gut pathogen? Gut Pathog. 2010 marz 21;2(1):2.

14. Cuervo CM, Gaviria AM. Detección de Helicobacter pylori en muestras de agua y biopelícula de los grifos de las instituciones educativas oficiales en la ciudad de Medellín. Acta Med Colomb. 2017;42(2):121-8.

15. Zeng M, Mao XH, Li JX, Tong W De, Wang B, Zhang YJ, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled,
phase 3 trial. Lancet. 2015;386(10002):1457-64.

16. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151(2):121-8.

17. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012;61(5):646-64.

18. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34(11-12):1255-68.

19. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther. 2005;21(1):91-6.

20. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther. 2005;22(1):45-9.

21. Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter. 2005;10(3):157-71.

22. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther. 2004;20(10):1071-82.

23. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med. 2015;54(7):703-10.

24. Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone sequential therapy for Helicobacter pylori: A meta-analysis. Pharmacotherapy. 2015;35(8):719-30.

25. Otero R W, Trespalacios R AA, Otero P L, Vallejo O MT, Torres Amaya M, Pardo R, et al. Clinical practice guideline for the diagnosis and management of adult patients with Helicobacter pylori infection. Rev Colomb Gastroenterol. 2015;30(Suppl. 1):17-33.

26. Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2015;(7):CD005583.

27. Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016;4:CD003840.

28. Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016;(6):CD009034.

29. Harb AH, Chalhoub JM, Abou Mrad R, Sharara AI. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2015;42(2):131-41.

30. Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol. 2015;21(45):12954-62.

31. Kim JS, Park SM, Kim B-W. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30(9):1338-45.

32. Lee SW, Kim HJ, Kim JG. Treatment of Helicobacter pylori Infection in Korea: A systematic review and meta-analysis. J Korean Med Sci. 2015;30(8):1001-9.

33. Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: Systematic review and network meta-analysis. BMJ. 2015;351:h4052.

34. Losurdo G, Leandro G, Principi M, Giorgio F, Montenegro L, Sorrentino C, et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by “geographical
weighting”. Int J Clin Pract. 2015;69(10):1112-20.

35. López-Góngora S, Puig I, Calvet X, Villoria A, Baylina M, Muñoz N, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob
Chemother. 2015 sep;70(9):2447-55.

36. Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, et al. Meta-analysis: Is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol. 2015;21(8):2522-33.

37. Teng M, Khoo AL, Zhao YJ, Lin L, Lim BP, Wu TS, et al. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. J Clin Pharm Ther. 2015;40(4):368-75.

38. Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, et al. Efficacy and safety of hybrid therapy for Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter. 2015;20(2):79-88.

39. Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, et al. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;43(4):470-81.

40. Niv Y. Doxycycline in eradication therapy of Helicobacter pylori: A systematic review and meta-analysis. Digestion. 2016;93(2):167-73.

41. Ren Q, Yan X, Zhou Y, Li WX. Periodontal therapy as adjunctive treatment for gastric Helicobacter pylori infection. Cochrane Database Syst Rev. 2016;2:CD009477.

42. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41(12):1237-45.

43. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-57.

44. Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G. Tailored therapy versus empiric chosen treatment for Helicobacter pylori eradication: A meta-analysis. Medicine (Baltimore). 2016;95(7):e2750.

45. Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci. 2015;30(6):749-56.

46. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the Treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51-69.e14.

47. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.

48. Fashner J, Gitu AC. Diagnosis and treatment of peptic ulcer disease and H. pylori infection. Am Fam Physician. 2015;91(4):236-42.

49. Mobley HL. Defining Helicobacter pylori as a pathogen: Strain heterogeneity and virulence. Am J Med. 1996;100(5A):2S-9S; discussion 9S-11S.

50. Hu Y, Wan J-H, Li X-Y, Zhu Y, Graham DY, Lu N-H. Systematic review with meta-analysis: The global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. noviembre de 2017;46(9):773-9.

51. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: A systematic review. J Gastrointest Liver Dis. 2010;19(4):409-14.

52. Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernández-García T, et al. The problem of Helicobacter pylori resistance to antibiotics: A systematic review in Latin America. Am J Gastroenterol.
2014;109(4):485-95.

53. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.

54. Zou QH, Li RQ. Helicobacter pylori in the oral cavity and gastric mucosa: A meta-analysis. J oral Pathol Med. 2011;40(4):317-24.

55. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Prim. 2016;2:16076.
Cómo citar
Laserna Estrada, A., Barahona Correa, J., & Alba Talero, L. (2018). Manejo de la infección por Helicobacter pylori: apreciación crítica de la literatura. Universitas Medica, 59(3), 1-13. https://doi.org/10.11144/Javeriana.umed59-3.pylo
Sección
Artículos de revisión
Artículos más leídos del mismo autor/a